Annals of Surgical Oncology Cite Track
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
10.1245/ASO.2005.08.019
Annals of Surgical Oncology 12:504-509 (2005)
© 2005 Society of Surgical Oncology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Smith, F. M.
Right arrow Articles by Redmond, H. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smith, F. M.
Right arrow Articles by Redmond, H. P.

Original Article

Sentinel Nodes Are Identifiable in Formalin-Fixed Specimens After Surgeon-Performed Ex Vivo Sentinel Lymph Node Mapping in Colorectal Cancer

Fraser McLean Smith, AFRCSI1, John Calvin Coffey, PhD, AFRCSI1, Nurul Mod Khasri, AFRCP1, Miriam Fiona Walsh, MbBCh, BAO2, Nollaig Parfrey, FRCP1, Eoin Gaffney, MD2, Richard Stephens, FRCSI2, M. John Kennedy, MRCPI2, William Kirwan, FRCSI1 and H. Paul Redmond, FRCSI1

1 Departments of Academic Surgery and Pathology, Cork University Hospital, Wilton, Cork, Ireland
2 Departments of Academic Surgery, Pathology, and Clinical and Molecular Oncology, St James’s Hospital, Dublin, Ireland

Correspondence: Address correspondence and reprint requests to: H. Paul Redmond, FRCSI; E-mail: redmondhp{at}shb.ie.

Background: In recent years, the technique of sentinel lymph node (SLN) mapping has been applied to colorectal cancer. One aim was to ultrastage patients who were deemed node negative by routine pathologic processing but who went on to develop systemic disease. Such a group may benefit from adjuvant chemotherapy.

Methods: With fully informed consent and ethical approval, 37 patients with primary colorectal cancer and 3 patients with large adenomas were prospectively mapped. Isosulfan blue dye (1 to 2 mL) was injected around tumors within 5 to 10 minutes of resection. After gentle massage to recreate in vivo lymph flow, specimens were placed directly into formalin. During routine pathologic analysis, all nodes were bivalved, and blue-staining nodes were noted. These later underwent multilevel step sectioning with hematoxylin and eosin and cytokeratin staining.

Results: SLNs were found in 39 of 40 patients (98% sensitivity), with an average of 4.1 SLNs per patient (range, 1–8). In 14 of 16 (88% specificity) patients with nodal metastases on routine reporting, SLN status was in accordance. Focused examination of SLNs identified occult tumor deposits in 6 (29%) of 21 node-negative patients. No metastatic cells were found in SLNs draining the three adenomas.

Conclusions: The ability to identify SLNs after formalin fixation increases the ease and applicability of SLN mapping in colorectal cancer. Furthermore, the sensitivity and specificity of this simple ex vivo method for establishing regional lymph node status were directly comparable to those in previously published reports.

Key Words: Colorectal • Sentinel node • Ex vivo • Micrometastasis • Ultrastaging






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the Society of Surgical Oncology.